Category News

Bristol Myers Squibb & Cellares Strike $380M Deal to Boost CAR T Cell Therapy Production

Bristol Myers Squibb (NYSE: BMY) and Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) dedicated to cell therapy manufacturing, have announced a significant worldwide capacity reservation and supply agreement. Valued at up to $380M in upfront and milestone payments,…

Read MoreBristol Myers Squibb & Cellares Strike $380M Deal to Boost CAR T Cell Therapy Production

Astellas Verifies Unfavourable District Court Ruling on Preliminary Injunction Against Lupin and Zydus’ MyrbetriqTM Generics

Astellas Pharma Inc. has confirmed that the U.S. District Court for the District of Delaware has issued a Report and Recommendation advising against granting Astellas’ motion for a preliminary injunction. This motion sought to prevent Lupin and Zydus from introducing…

Read MoreAstellas Verifies Unfavourable District Court Ruling on Preliminary Injunction Against Lupin and Zydus’ MyrbetriqTM Generics

Grifols Marks 50 Years of Transformative Plasma Medicine Production in Clayton, N.C

Grifols, a global healthcare leader renowned for its plasma-derived medicines, commemorated the 50th anniversary of its Clayton, N.C. flagship facility today. Since its inception, this site has been pivotal in delivering life-saving therapies to countless patients worldwide. Originally established as…

Read MoreGrifols Marks 50 Years of Transformative Plasma Medicine Production in Clayton, N.C

Jumar Bioincubator: Pioneering Mini Brain & Lab-on-a-Chip Tech to Create Australia’s Next CSL

Australia’s Newest Biotech Incubator, Jumar Bioincubator, Opens with Ambitious Ventures Jumar Bioincubator has officially launched in Melbourne, welcoming its first cohort of 16 pioneering early-stage ventures. The event, graced by Lord Mayor Sally Capp AO, showcased the cutting-edge facilities and…

Read MoreJumar Bioincubator: Pioneering Mini Brain & Lab-on-a-Chip Tech to Create Australia’s Next CSL

NEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING

Peptide manufacturing for commercial-scale production primarily employs two main methodologies: synthetic and recombinant. Each method presents unique advantages and challenges, crucial for stakeholders in the pharmaceutical industry to consider when determining the most suitable production strategy. In this article, we’ll…

Read MoreNEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING

Supporting Save the Children Finland: Orion’s Donation Ensures No Child or Young Person Copes Alone

The rising cost of living compounds the difficulties faced by low-income families with children, creating an urgent need for support, says Heidi Herranen, Coordinator of Save the Children Finland’s Fuel for Life Programme. Orion’s donation of EUR 50,000, split between…

Read MoreSupporting Save the Children Finland: Orion’s Donation Ensures No Child or Young Person Copes Alone

Updated Terminology for Airborne Pathogens Released by Leading Health Agencies

In collaboration with public health agencies and experts worldwide, the World Health Organization (WHO) has released a comprehensive report introducing updated terminology for pathogens transmitted through the air. The report, titled “Global Technical Consultation Report on Proposed Terminology for Airborne…

Read MoreUpdated Terminology for Airborne Pathogens Released by Leading Health Agencies